Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online January 26, 2006
Stem Cells Vol. 24 No. 5 May 2006, pp. 1194 -1200
doi:10.1634/stemcells.2005-0349; www.StemCells.com
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-0349v1
24/5/1194    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, D.-I.
Right arrow Articles by Shim, J.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, D.-I.
Right arrow Articles by Shim, J.-S.

TRANSLATIONAL AND CLINICAL RESEARCH

Angiogenesis Facilitated by Autologous Whole Bone Marrow Stem Cell Transplantation for Buerger’s Disease

Dong-Ik Kima, Mi-Jung Kimd, Jin-Hyun Joha, Sung-Wook Shinb, Young-Soo Dob, Ji-Young Moona, Na-Ri Kima, Joung-Eun Limf, Ae-Kyeong Kimf, Hyun-Seon Eof, Byung-Soo Kime, Seung-Woo Chog, Seung-Hye Yangd, Chan-Jeoung Parkd, Jong-Sup Shimc

a Division of Vascular Surgery and
b Departments of Radiology and
c Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;
d Department of Laboratory Medicine, University of Ulsan College of Medicine, Asan Institute for Life Sciences, Seoul, Korea;
e Department of Bioengineering, Hanyang University, Seoul, Korea;
f Samsung Biomedical Research Institute,
g School of Chemical and Biological Engineering, Seoul National University, Seoul, Korea

Key Words. Angiogenesis • Bone marrow • Stem cells

Correspondence: Dong-Ik Kim, M.D., Ph.D., Division of Vascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwondong, Kangnamku, Seoul 135-710, Korea. Telephone: 82-2-3410-3467; Fax: 82-2-3410-0040; e-mail: dikim{at}smc.samsung.co.kr or Mi-Jung Kim, Department of Laboratory Medicine, University of Ulsan College of Medicine, Asan Institute for Life Sciences, 388 Pungnap-2 dong, Songpa-gu, Seoul 138-736, Korea. Telephone: 82-2-3010-4147; Fax: 82-2-3010-4182; E-mail: mijkim{at}amc.seoul.kr

Received July 29, 2005; accepted for publication January 17, 2006.
We hypothesized that angiogenesis can be triggered by autologous whole bone marrow stem cell transplantation. Twenty-seven patients (34 lower limbs) with Buerger’s disease, who were not candidates for surgical revascularization or radiologic intervention, were enrolled in this study. Six sites of the tibia bone were fenestrated using a 2.5-mm-diameter screw under fluoroscopic guidance. Clinical status and outcome were determined using the "Recommended Standards for Reports." To mobilize endothelial progenitor cells (EPCs) from bone marrow, recombinant human granulocyte colony-stimulating factor (r-HuG-CSF) was injected subcutaneously as a dose of 75 µg, preoperatively. During the follow-up period (19.1 ± 3.5 months), one limb showed a markedly improved outcome (+3), and 26 limbs showed a moderately improved outcome (+2). Thirteen limbs among 17 limbs with nonhealing ulcers healed. Postoperative angiograms were obtained for 22 limbs. Two limbs showed marked (+3), five limbs moderate (+2), and nine limbs slight (+1) collateral development. However, six limbs showed no collateral development (0). Peripheral blood and bone marrow samples were analyzed for CD34 and CD133 molecules to enumerate potential EPCs, and EPC numbers were found to be increased in peripheral blood and in bone marrow after r-HuG-CSF injection. In conclusion, the transplantation of autologous whole BMCs by fenestration of the tibia bone represents a simple, safe, and effective means of inducing therapeutic angiogenesis in patients with Buerger’s disease.




This article has been cited by other articles:


Home page
JAMAHome page
R. K. Burt, Y. Loh, W. Pearce, N. Beohar, W. G. Barr, R. Craig, Y. Wen, J. A. Rapp, and J. Kessler
Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases
JAMA, February 27, 2008; 299(8): 925 - 936.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
X. Puechal and J.-N. Fiessinger
Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist
Rheumatology, February 1, 2007; 46(2): 192 - 199.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.peprotech.com/
Copyright © 2006 by AlphaMed Press.